AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.

Mene Pangalos to retire AZ also revealed that its long-serving head of R&D, Mene Pangalos, will retire at the start of 2024 and be replaced by Sharon Barr, who is currently senior vice president ...

AstraZeneca could receive up to $400m from Takeda to jointly develop and market a potential new treatment for Parkinson’s disease (PD).

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy ...

Mene Pangalos, executive vice president, IMED Biotech Unit and Business Development, AZ, added: "MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a ...

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

Mene Pangalos, executive vice president BioPharmaceuticals R&D, AstraZeneca said: “Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new ...

The FDA has started a priority review of AstraZeneca and Amgen's severe asthma antibody tezepelumab, setting a date for a decision in the first quarter of 2022. If approved, TSLP inhibitor ...

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR). The deal is another sizeable ...

Menelas Pangalos, Executive Vice President, Innovative Medicines and Early Development at AstraZeneca, said: "This major strategic alliance with the MRC is the first of its kind.